Percutaneous Coronary Interventions Using a Ridaforolimus‐Eluting Stent in Patients at High Bleeding Risk

Percutaneous Coronary Interventions Using a Ridaforolimus‐Eluting Stent in Patients at High Bleeding Risk

Background Patients treated with percutaneous coronary intervention are often considered to be at a high bleeding risk (HBR). Drug‐eluting stents have been shown to be superior to bare‐metal stents in patients with HBR, even when patients were given abbreviated periods of dual antiplatelet therapy (...

Full description

Bibliographic Details
Main Authors: Ran Kornowski, Maayan Konigstein, Michael Jonas, Abid Assali, Hana Vaknin‐Assa, Amit Segev, Haim Danenberg, Majdi Halabi, Ariel Roguin, Arthur Kerner, Eli Lev, Grigoris V. Karamasis, Thomas W. Johnson, Richard Anderson, Jonathan Blaxill, Sachin Jadhav, Stephen Hoole, Guy Witberg, Melek Ozgu Issever, Ori Ben‐Yehuda, Andreas Baumbach
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
antithrombotic therapy
coronary artery disease
high bleeding risk
percutaneous coronary intervention
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.029051

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.029051

Similar Items